By Nancy Corbitt, BSN, RN, OCN®, CRNI
A newly-diagnosed patient with Acute Promyelocytic Leukemia (APL) arrives to your floor and is under your care for the next 12 hours. It is very likely that this particular patient will be experiencing disseminated intravascular coagulation (DIC) due to the presenting disease. You’ll need to transfuse multiple blood products to the patient to ensure a positive outcome.
Whether you work inpatient or outpatient oncology, transfusing blood products can be a daily task. Have you ever wondered why blood products need to be irradiated, leukocyte reduced, or Cytomegalovirus (CMV) negative for the oncology population? If you have been practicing for a while, have you noticed that the transfusion threshold for platelets and packed red bloods has changed? What does the evidence tell us?
Attend “Grand Rounds: Acute Promyelocytic Leukemia (APL) and Unique Blood Product Requirements,” presented by Nicole Draper, MD, on Saturday morning of Congress to discuss the need for multiple and different types of blood products. You’ll experience a case-based study of a new APL patient and will also discuss the nuts and bolts of blood product administration.
Be sure to mark your schedule for Saturday, April 30, from 9:45–11 am to hear this intriguing presentation about APL and best practices for blood product infusions.